EXTENSANCT07919899
Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Ctrough,ss at Week 20
Timeframe: Week 20
Secondary (6)
AUC0-4 weeks,ss
Cmax,ss
Incidence of TEAEs, TE-AESIs, TE-SAEs, and TEAEs leading to permanent treatment discontinuation in the treatment-emergent period
Incidence of potentially clinically significant abnormalities in laboratory test, vital signs, and ECGs abnormalities in the treatment-emergent period
Incidence of treatment-emergent anti-drug antibody (ADA) to dupilumab through Week 20
Show 1 moreShow less
Incidence of treatment-emergent ADA to ALT-B4 through Week 20
Arms and interventions
Dupilumab coformulated with berahyaluronidase alfaExperimental
dupilumab coformulated with berahyaluronidase alfa SC injection as per protocol
Dupilumab approved formulationActive comparator
Approved dupilumab SC injection as per protocol
Drugs: Dupilumab coformulated with berahyaluronidase alfa, Dupilumab